Your browser doesn't support javascript.
loading
Efficacy of treatment patterns based on concurrent chemoradiotherapy in patients with stage IIB cervical squamous cell carcinoma.
Pan, Xin-Bin; Lu, Yan; Wei, You-Sheng; Yao, De-Sheng.
Afiliación
  • Pan XB; Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, 530021, Nanning, Guangxi, P.R. China.
  • Lu Y; Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, 530021, Nanning, Guangxi, P.R. China.
  • Wei YS; Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, 530021, Nanning, Guangxi, P.R. China.
  • Yao DS; Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, 530021, Nanning, Guangxi, P.R. China. yaodesheng@aliyun.com.
BMC Cancer ; 24(1): 106, 2024 Jan 18.
Article en En | MEDLINE | ID: mdl-38238689
ABSTRACT

PURPOSE:

To assess survival of treatment patterns based on concurrent chemoradiotherapy (CCRT) in patients with stage IIB cervical squamous cell carcinoma (CSCC). MATERIALS AND

METHODS:

Patients with stage IIB CSCC receiving CCRT were investigated from June 2012 to June 2019 in Guangxi Medical University Cancer Hospital. Baseline characteristics and treatment patterns were described. Survival between treatment patterns were compared using Kaplan-Meier methods.

RESULTS:

A total of 232 patients were included 39.7% of patients received CCRT alone, 6.5% of patients received neoadjuvant chemotherapy (NACT) + CCRT, 45.6% of patients received CCRT + adjuvant chemotherapy (AC), and 8.2% of patients received NACT + CCRT + AC. CCRT + AC showed similar overall survival (OS; hazard ratio [HR] = 0.95, 95% confidence interval [CI] 0.41-2.17; P = 0.894) and locoregional-free survival (LRFS; HR = 2.39, 95% CI 0.45-12.63; P = 0.303) compared with CCRT. However, CCRT + AC had a worse distant metastasis-free survival (DMFS; HR = 5.39, 95% CI 1.14-25.57; P = 0.034). After propensity score matching, CCRT + AC had comparable OS (HR = 0.89, 95% CI 0.29-2.70; P = 0.833), LRFS (HR = 3.26, 95% CI 0.30-35.38; P = 0.331), and DMFS (HR = 4.80, 95% CI 0.55-42.26; P = 0.157) compared to CCRT.

CONCLUSION:

AC did not improve survival in patients with stage IIB CSCC receiving CCRT.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Neoplasias del Cuello Uterino / Neoplasias Nasofaríngeas Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Female / Humans País/Región como asunto: Asia Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Neoplasias del Cuello Uterino / Neoplasias Nasofaríngeas Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Female / Humans País/Región como asunto: Asia Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido